Message From Senior Management
601 21st Street, Suite 300 Vero Beach, FL 32960 February 11, 2025 Dear Shareholder: Our fiscal year will end March 31, 2025, and this year has proven to be challenging, yet productive. We [...]
Pritumumab is a proprietary monoclonal antibody (mAb) targeting a novel antigen on cancer cells.
Pritumumab has received FDA orphan drug status
NASCENT BIOTECH NEWS
